Page 124«..1020..123124125126..130140..»

Where Does Cogent Biosciences Inc (COGT) Stock Fall in the Biotechnology Field After It Is Higher By 0.08% This Week? – InvestorsObserver

Posted: December 18, 2022 at 12:52 am

Where Does Cogent Biosciences Inc (COGT) Stock Fall in the Biotechnology Field After It Is Higher By 0.08% This Week?  InvestorsObserver

Read more:
Where Does Cogent Biosciences Inc (COGT) Stock Fall in the Biotechnology Field After It Is Higher By 0.08% This Week? - InvestorsObserver

Posted in Biotechnology | Comments Off on Where Does Cogent Biosciences Inc (COGT) Stock Fall in the Biotechnology Field After It Is Higher By 0.08% This Week? – InvestorsObserver

PUMA BIOTECHNOLOGY, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form…

Posted: December 18, 2022 at 12:52 am

PUMA BIOTECHNOLOGY, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)  Marketscreener.com

Go here to read the rest:
PUMA BIOTECHNOLOGY, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form...

Posted in Biotechnology | Comments Off on PUMA BIOTECHNOLOGY, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form…

Can This Companys Research Help Transform Regenerative Medicine As Its …

Posted: December 18, 2022 at 12:49 am

Learn More about Organicell Regenerative Medicine, Inc. by gaining access to the latest research report

In the medical community, the popularity of regenerative medicine is reportedly soaring primarily because research around these therapies shows promise in treating a wide range of musculoskeletal pain conditions.

Armed with the belief that the human body can heal itself, regenerative medicine treatments like exosome therapy and stem cell therapy are advancing.

But regenerative medicine has sometimes been embroiled in controversy beginning in 1981 when scientistsdiscoveredways to derive embryonic stem cells from early mouse embryos.

That discovery was followed by a method to derive stem cells from human embryos and grow the cells in the laboratory in 1998.

Massive players likeAmgen Inc.AMGN,Sanofi SASNY, andGilead Sciences Inc.GILD have advanced stem cell research and therapies.

Unlike stem cell therapy, Organicells OCEL exosome therapy doesn'tinvolveusing donor cells or umbilical cords. Instead, the exosomes are extracted from full term, planned C Section, Amniotic fluid. The extracted exosome solution is derived from amniotic fluid and contains over 300 soluble proteins as growth factors, cytokines and chemokines, extracellular matrix proteins as fibronectin and collagen, structural molecules as hyaluronic acid, Nanoparticles as extracellular vesicles, exosomes and surfactants proteins, valuable lipids, micro-RNA, messenger-RNA, and cytokines.

Exosome therapy, according toexperts, is a highly targeted, flexible treatment believed to help inflammatory conditions like COPD, Long Covid, musculoskeletal injuries, osteoarthritis, and chronic pain.

Try to think of Stem Cells as microchips in a computer. Exosomes are like the software.

South Florida-basedOrganicell Regenerative Medicine Inc.OCEL is a company that is a pioneer in the exosome space. Their products are designed to operate like software for the computers of our body known as cells. However, the software Organicell uses is naturally occurring and unaltered. Organicell extracts its exosomes from what is believed to be one of the most naturally healing fluids on the planet, amniotic fluid. The software/exosomes in this fluid reminds the body what it used to do when it was young.

To put things plainly, the software (exosomes) is a set of instructions, data or programs used to operate the computers (cells) and execute specific tasks, while a computer-chip (stem cells) are used more as building blocks in regenerative medicine.

The potential benefits of Organicells products could be enormous. For example, the company's investigational productZofinis an acellular, non-HCT/P biologic, currently being studied in clinical trials. The company accomplished the difficult task of an approved investigational new drug (IND)from the U.S. Food and Drug Administration (FDA) which lead to approved clinical trials..

Zofin is derived from perinatal sources and is manufactured to retain the naturally occurring nanoparticles andmicroRNAswithout manipulation or adding or combining any other substance.

Zofin is currently being studied in FDAPhase I/II clinical trials for COVID-19, Long Covid, Chronic Obstructive Pulmonary Disease (COPD), and ready to begin a trial for Osteoarthritis of the knee.

Below are the results that were published on the COVID patients treated with Zofin under eIND approval. The important items in the chart are the key biomarkers that measure inflammation: IL-6 and CRP as well as the chest X Rays that show the structural difference in the lungs over time.

Organicellreports that its mission is to be the first company to prove the efficacy ofextracellular vesicles (EV's) a.k.a exosomes on inflammatory ailments. Organicell has two active FDA approved clinical trials for Long Covid and COPD.

The company says through its ground-breaking research in the field of nanotechnology, specifically perinatal-derived EVs, it has created the drug candidate, Zofin, that could be the next frontier of regenerative biologic therapeutics.

Organicells proprietary products biological representation is allogenic amniotic fluid (secreted body fluid, non-HCT/Ps), which is an acellular product derived from human amniotic fluid (HAF). The product contains no addition or combination of any other substance or diluent during production.

Moreover, the product quality assurance is seemingly unmatched in the regenerative medicine space. the donor from whom this product was derived has been tested and found negative for the following: HBsAg (Hepatitis B Surface Antigen), HBcAb (hepatitis B core antibody), HCV (hepatitis C antibody), HIV I/II-Ab (Antibody to Human Immunodeficiency Virus Types 1 and 2), Syphilis detection test, HIV NAT (HIV Nucleic Acid Test), and HCV NAT (HCV Nucleic Acid Test).

Additional donor screening tests may have been performed on the donor. If additional tests for Human Immunodeficiency Virus, Hepatitis B, Hepatitis C or Syphilis were performed, the results were reviewed and found to be NEGATIVE.

Additional tests for other communicable diseases, such as West Nile Virus, T. Cruzi, Cytomegalovirus and Epstein Barr Virus may have been performed. The results of all additional communicable disease tests have been evaluated by the Medical Director and have been found acceptable according to regulations, standards and Standard Operating Procedures (SOPs).

Donor screening tests are performed by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and American Association of Blood Banks (AABB) using FDA licensed tests when available performed by VRL Laboratories.

The donor is selected based on medical and social history which meets the Standards of the American Association of Tissue Banks (AATB) United States Public Health Service (USPHS), and the Federal Food and Drug Administration (FDA).

Donor suitability was determined by the Manufacturing Facilities Medical Directors (Organicell Regenerative Medicine, 1951 NW 7th Ave, Suite 300, Miami, FL 33136). Organicell Factor X is manufactured for clinical use under cGMP-compliant manufacturing facility, to control potency and purity of the product.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Featured Photo by Shutterstock

Read the original post:
Can This Companys Research Help Transform Regenerative Medicine As Its ...

Posted in Regenerative Medicine | Comments Off on Can This Companys Research Help Transform Regenerative Medicine As Its …

Transhumanist Party – Wikipedia

Posted: December 18, 2022 at 12:42 am

American political party

The Transhumanist Party is a political party in the United States. The party's platform is based on the ideas and principles of transhumanist politics, e.g., human enhancement, human rights, science, life extension, and technological progress.[3][4][5]

The Transhumanist Party was founded in 2014 by Zoltan Istvan. Istvan became the first political candidate to run for office under the banner of the Transhumanist Party when he announced his candidacy for President of the United States in the United States presidential election of 2016.[4] As part of his campaign Zoltan and a cadre of transhumanist activists and embedded journalists embarked on a four-month journey in the coffin-shaped Immortality Bus, which traveled on a winding cross-country route from San Francisco to Washington D.C. The Transhumanist Party has been featured or mentioned in many major media sites, including the National Review,[6] Business Insider,[7] Extreme Tech, Vice,[8] Wired,[9] The Telegraph, The Huffington Post,[4] The Joe Rogan Experience,[10] Heise Online,[11] Gizmodo,[12] and Reason.[13] Political scientist Roland Benedikter said the formation of the Transhumanist Party in the USA was one of three reasons transhumanism entered into the mainstream in 2014, creating "a new level of public visibility and potential impact."[14]

Following the end of the 2016 presidential election, after Zoltan's 2016 presidential campaign was completed, Gennady Stolyarov II became the Chairman of the party and the organisation was restructured. Under Chairman Stolyarov, the party adopted a new Constitution,[15] which included three immutable Core Ideals in Article I, Section I:[16]

New positions were founded, including Pavel Ilin became Secretary, Dinorah Delfin Director of Admissions and Public Relations, Arin Vahanian as Director of Marketing, Sean Singh as Director of Applied Innovation, Brent Reitze as Director of Publication, Franco Cortese as Director of Scholarship, and B.J. Murphy as Director of Social Media.[17] Restructured advisor positions included Zoltan Istvan as Political and Media Advisor, Bill Andrews as Biotechnology Advisor, Jose Cordeiro as Technology Advisor, Newton Lee as Education and Media Advisor, Keith Comito as Crowdfunding Advisor, Aubrey de Grey as Anti-Aging Advisor, Rich Lee as Biohacking Advisor, Katie King as Media Advisor, Ira Pastor as Regeneration Advisor, Giovanni Santostasi as Regeneration Advisor, Elizabeth Parrish as Advocacy Advisor, and Paul Spiegel as Legal Advisor.

The U.S. Transhumanist Party held six Platform votes during January, February, March, May, June, and November 2017, on the basis of which 82 Platform planks were adopted.[18] The U.S. Transhumanist Party holds votes of its members electronically and is the first political party in the United States to use ranked-preference voting method with instant runoffs in its internal ballots.[19]

In May 2018 the New York Times reported the U.S. Transhumanist Party as having 880 members.[20] On July 7, 2018, the U.S. Transhumanist Party reached 1,000 members and released a demographic analysis of its membership.[1] This analysis showed that 704 members, or 70.4%, were eligible to vote in the United States, whereas 296 or 29.6% were allied members.

During this time, the Transhumanist Party hosted several expert discussion panels, on subjects including artificial intelligence,[21] life extension,[22] art and transhumanism,[23] and cryptocurrencies.[24] Chairman Stolyarov has also hosted in-person Enlightenment Salons, which were aimed at cross-disciplinary discussion of transhumanist and life-extensionist ideas under the auspices of the U.S. Transhumanist Party.[25][26][27]

On August 11, 2017, at the RAAD Fest 2017 conference in San Diego, California, Chairman Stolyarov gave an address entitled "The U.S. Transhumanist Party: Pursuing a Peaceful Political Revolution for Longevity", which provided an overview of the U.S. Transhumanist Party's key principles and objectives.[28] In October 2017 Hank Pellissier founded the "Transhuman Party" following a trademark dispute with Zoltan Istvan's continued ownership of the 'Transhumanist Party' trademark. In response to Pellissier, the U.S. Transhumanist Party published its FAQ, where a significant portion was devoted to explaining the history of the U.S. Transhumanist Party, its current interactions with Zoltan Istvan and the scope of his involvement, and the reasons for his continued ownership of the 'Transhumanist Party' trademark.[29] The Transhuman Party became defunct in late 2017 due to lack of activity and its domain name and Facebook page were acquired by the US Transhumanist Party.[2]

By September 2017 the Party had appointed a number of international ambassadors, from Brazil, Bulgaria, Canada, Chile, Egypt, England, Hong Kong, India, Nigeria, and Scotland.[30] On November 9, 2017, in a virtual presentation at the TransVision 2017 conference in Brussels, Belgium, Chairman Stolyarov gave an overview of the U.S. Transhumanist Party's achievements in 2017 and future aspirations.[31] On March 31, 2018, Chairman Stolyarov was interviewed by Nikola Danaylov, a.k.a. Socrates, of Singularity.FM during a three-hour session, the longest of all of Danaylov's interviews.[32]

The Transhumanist Party presidential primary attracted media attention from BioEdge[33] and the Milwaukee Record.[34] While some media outlets reported Zoltan Istvan was considering running again,[35] ultimately he did not join the party's primary. After a protracted primary process with nine candidates, featuring numerous debates,[36] Johannon Ben Zion was elected as the party's nominee. After winning the primary, Ben Zion gave his acceptance speech at RAAD Fest 2019 in Las Vegas.[37] and filed with the FEC.[38] Shortly thereafter, film producer, entrepreneur, and longevity organizer Charlie Kam became Ben Zion's running mate. On October 19, 2019, Ben Zion spoke to the DC Transhumanists meetup in Arlington, VA.[39] On November 3, 2019, he spoke at the Foresight Institute's Vision Weekend Event in San Francisco. On November 24, 2019, he spoke to undergraduates at Princeton University as part of the Princeton Envision conference.[40] On March 4, 2020, Ben Zion participated in the Free & Equal Elections Foundation's Open Presidential debate in Chicago, Illinois.[41] Zoltan Istvan also participated in the debate, running as a Republican.[42]

On June 12, 2020, it was announced that Ben Zion had left the Transhumanist Party, with him declaring that his belief in Techno-progressivism was incompatible with the party, and that he would instead be pursuing a run for the Reform Party nomination. Kam was declared the replacement presidential nominee.[43][44] In June 2020 Charlie Kam participated in a panel with London Futurists and in July 2020 his campaign received press coverage in the Daily Express.[45] On August 21, 2020, Kam announced his selection of Elizabeth (Liz) Parrish as his vice-presidential running mate.[46]

A few days after his departure from the party, Ben Zion published a video purporting to show him eating a cellular culture of his own skin cells which reportedly were grown in the lab of a startup he is affiliated with, Quixotic Life Sciences.[47][48] In a statement disavowing the stunt published on the USTP website, it was noted that USTP officers previously warned Ben Zion that he would be disavowed if he pursued this reckless project.[49]

A core tenet of the USTP platform is that more funding is needed for research into human life extension research and research to reduce existential risk. More generally, the goal is to raise awareness among the general public about how technologies can enhance the human species.[18][51] Democratic transhumanists and libertarian transhumanists tend to be in disagreement over the role of government in society, but both agree that laws should not encumber technological human progress.[52]

The Transhumanist Party platform promotes national and global prosperity by sharing technologies and creating enterprises to lift people and nations out of poverty, war, and injustice.[53][54] The Transhumanist Party also supports LGBT rights, drug legalization, and sex work legalization. The party seeks to fully subsidize university-level education while also working to "create a cultural mindset in America that embracing and producing radical technology and science is in the best interest of our nation and species."[4][55]

In terms of foreign policy and national defense, the party wants to reduce the amount of money spent on foreign wars and use the money domestically.[3] The party also advocates managing and preparing for existential risks, eliminating dangerous diseases, and proactively guarding against abuses of technology, such as nanotechnology, synthetic viruses, and artificial intelligence.[3][4]

The USTP expressly supports the rights of Artificial General Intelligence entities that are sentient and/or lucid. The Transhumanist Bill of Rights Version 3.0 recognizes 7 levels of sentience, and requires entities to exist at level 5 or higher to be considered as having rights. At level 5, the main criterion is that the entity be "lucid", meaning the entity is "meta-aware", or aware of its own awareness.[56]

The various policy points of the US Transhumanist Party's platform have attracted both praise and criticism from sociologist Steve Fuller. For example, Fuller has praised the centrality of morphological freedom in the US Transhumanist Party's bill of rights,[57] but on the other hand he has also written that the party is too critical of the US Department of Defense, which he argues could be an ally for some transhumanist initiatives such as human enhancement and existential risk reduction.[58] In 2018 the party as a whole was reviewed favorably as an example of a successful "niche" party by Krisztian Szabados, a director at the Edmond J. Safra Center for Ethics at Harvard University.[59]

The Transhumanist Party in Europe is the umbrella organization that supports the national level transhumanist parties in Europe by developing unified policies and goals for the continent.[61][62] Among them is the UK Transhumanist Party, which was founded in January 2015.[63][64][65] In October 2015, Amon Twyman, the party's leader at the time, published a blog post distancing the UK party from Zoltan Istvan's campaign.[66]

Follow this link:
Transhumanist Party - Wikipedia

Posted in Transhumanist | Comments Off on Transhumanist Party – Wikipedia

Tumor buster – where will the CAR-T cell therapy missile go?

Posted: December 18, 2022 at 12:40 am

Wang S, Sun J, Chen K, et al. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors. BMC Med. 2021;19(1):140.

Article Google Scholar

Singh AK, McGuirk JP. CAR T cells: continuation in a revolution of immunotherapy. Lancet Oncol. 2020;21(3):e16878. https://doi.org/10.1016/S1470-2045(19)30823-X.

Article CAS PubMed Google Scholar

Newick K, O'Brien S, Moon E, et al. CAR T cell therapy for solid tumors. Annu Rev Med. 2017;68:13952. https://doi.org/10.1146/annurev-med-062315-120245.

Article CAS PubMed Google Scholar

Zhang C, Liu J, Zhong JF, et al. Engineering CAR-T cells. Biomark Res. 2017;5:22. https://doi.org/10.1186/s40364-017-0102-y.

Article PubMed PubMed Central Google Scholar

Sadelain M, Brentjens R, Rivire I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):38898. https://doi.org/10.1158/2159-8290.CD-12-0548.

Article CAS PubMed PubMed Central Google Scholar

van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14(7):499509. https://doi.org/10.1038/nrd4597.

Article CAS PubMed PubMed Central Google Scholar

Marin V, Pizzitola I, Agostoni V, et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica. 2010;95(12):214452. https://doi.org/10.3324/haematol.2010.026310.

Article CAS PubMed PubMed Central Google Scholar

Roselli E, Boucher JC, Li G, et al. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. J Immunother Cancer. 2021;9(10). https://doi.org/10.1136/jitc-2021-003354.

Huang R, Li X, He Y, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13(1):86. https://doi.org/10.1186/s13045-020-00910-5.

Article CAS PubMed PubMed Central Google Scholar

Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):114554. https://doi.org/10.1517/14712598.2015.1046430.

Article CAS PubMed Google Scholar

Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell. 2018;173(6):14261438.e11. https://doi.org/10.1016/j.cell.2018.03.038.

Article CAS PubMed PubMed Central Google Scholar

Urbanska K, Lanitis E, Poussin M, et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 2012;72(7):184452. https://doi.org/10.1158/0008-5472.CAN-11-3890.

Article CAS PubMed PubMed Central Google Scholar

Ma JS, Kim JY, Kazane SA, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci U S A. 2016;113(4):E4508. https://doi.org/10.1073/pnas.1524193113.

Article CAS PubMed PubMed Central Google Scholar

Xie YJ, Dougan M, Jailkhani N, et al. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci U S A. 2019;116(16):762431. https://doi.org/10.1073/pnas.1817147116.

Article CAS PubMed PubMed Central Google Scholar

Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):58190. https://doi.org/10.1038/nm.3838.

Article CAS PubMed PubMed Central Google Scholar

Weatherill EE, Cain KL, Heywood SP, et al. Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation. Protein Eng Des Sel. 2012;25(7):3219. https://doi.org/10.1093/protein/gzs021.

Article CAS PubMed Google Scholar

Zhylko A, Winiarska M, Graczyk-Jarzynka A. The great war of today: modifications of CAR-T cells to effectively combat malignancies. Cancers (Basel). 2020;12(8). https://doi.org/10.3390/cancers12082030.

Wei J, Han X, Bo J, et al. Target selection for CAR-T therapy. J Hematol Oncol. 2019;12(1):62. https://doi.org/10.1186/s13045-019-0758-x.

Article PubMed PubMed Central Google Scholar

Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):18008. https://doi.org/10.1182/blood-2017-03-769620.

Article CAS PubMed PubMed Central Google Scholar

Mounier N, Canals C, Gisselbrecht C, et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European blood and marrow transplantation registry. Biol Blood Marrow Transplant. 2012;18(5):78893. https://doi.org/10.1016/j.bbmt.2011.10.010.

Article PubMed Google Scholar

Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma. 1995;18(5-6):38597. https://doi.org/10.3109/10428199509059636.

Article CAS PubMed Google Scholar

Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):4556.

Article CAS Google Scholar

Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet (London, England). 2020;396(10254):83952.

Article Google Scholar

Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):253144.

Article CAS Google Scholar

Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):64054. https://doi.org/10.1056/NEJMoa2116133.

Article CAS PubMed Google Scholar

Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):73542. https://doi.org/10.1038/s41591-022-01731-4.

Article CAS PubMed PubMed Central Google Scholar

Ghione P, Palomba ML, Patel A, et al. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood. 2022. https://doi.org/10.1182/blood.2021014375.

Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91103. https://doi.org/10.1016/S1470-2045(21)00591-X.

Article CAS PubMed Google Scholar

Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):24108. https://doi.org/10.1200/JCO.2017.72.7602.

Article CAS PubMed PubMed Central Google Scholar

Frigault MJ, Dietrich J, Gallagher K, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood. 2022;139(15):230615. https://doi.org/10.1182/blood.2021014738.

Article CAS PubMed Google Scholar

Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):133142. https://doi.org/10.1056/NEJMoa1914347.

Article CAS PubMed PubMed Central Google Scholar

Miles RR, Arnold S, Cairo MS. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. Br J Haematol. 2012;156(6):73043. https://doi.org/10.1111/j.1365-2141.2011.09024.x.

Article CAS PubMed Google Scholar

Russo-Carbolante EM, Picano-Castro V, Alves DC, et al. Integration pattern of HIV-1 based lentiviral vector carrying recombinant coagulation factor VIII in Sk-Hep and 293T cells. Biotechnol Lett. 2011;33(1):2331. https://doi.org/10.1007/s10529-010-0387-5.

Article CAS PubMed Google Scholar

Tao J, Zhou X, Jiang Z. cGAS-cGAMP-STING: the three musketeers of cytosolic DNA sensing and signaling. IUBMB Life. 2016;68(11):85870. https://doi.org/10.1002/iub.1566.

Article CAS PubMed Google Scholar

Gndara C, Affleck V, Stoll EA. Manufacture of third-generation lentivirus for preclinical use, with process development considerations for translation to good manufacturing practice. Hum Gene Ther Methods. 2018;29(1):115. https://doi.org/10.1089/hgtb.2017.098.

Article CAS PubMed PubMed Central Google Scholar

Atianand MK, Fitzgerald KA. Molecular basis of DNA recognition in the immune system. J Immunol. 2013;190(5):19118. https://doi.org/10.4049/jimmunol.1203162.

Article CAS PubMed Google Scholar

Michieletto D, Lusic M, Marenduzzo D, et al. Physical principles of retroviral integration in the human genome. Nat Commun. 2019;10(1):575. https://doi.org/10.1038/s41467-019-08333-8.

Article CAS PubMed PubMed Central Google Scholar

Zhang J, Hu Y, Yang J, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature. 2022. https://doi.org/10.1038/s41586-022-05140-y.

Doody GM, Justement LB, Delibrias CC, et al. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science. 1995;269(5221):2424. https://doi.org/10.1126/science.7618087.

Article CAS PubMed Google Scholar

Baird JH, Frank MJ, Craig J, et al. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. Blood. 2021;137(17):23215. https://doi.org/10.1182/blood.2020009432.

Article CAS PubMed PubMed Central Google Scholar

Zhang WY, Wang Y, Guo YL, et al. Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. Signal transduction and targeted. Therapy. 2016;1:16002.

Google Scholar

Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. BLOOD. 2012;119(17):394050.

Article CAS Google Scholar

Du J, Zhang Y. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review. J Cancer Res Clin Oncol. 2020;146(6):157582. https://doi.org/10.1007/s00432-020-03198-7.

Article CAS PubMed Google Scholar

Ramos CA, Savoldo B, Torrano V, et al. Clinical responses with T lymphocytes targeting malignancy-associated light chains. J Clin Invest. 2016;126(7):258896. https://doi.org/10.1172/JCI86000.

Article PubMed PubMed Central Google Scholar

Ranganathan R, Shou P, Ahn S, et al. CAR T cells targeting human immunoglobulin light chains eradicate mature B-cell malignancies while sparing a subset of Normal B cells. Clin Cancer Res. 2021;27(21):595160. https://doi.org/10.1158/1078-0432.CCR-20-2754.

Article CAS PubMed PubMed Central Google Scholar

Bunse M, Pfeilschifter J, Bluhm J, et al. CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells. Nat Commun. 2021;12(1):240. https://doi.org/10.1038/s41467-020-20488-3.

Article CAS PubMed PubMed Central Google Scholar

Spiegel JY, Patel S, Muffly L, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27(8):141931. https://doi.org/10.1038/s41591-021-01436-0.

Article CAS PubMed PubMed Central Google Scholar

Zhang Y, Li J, Lou X, et al. A prospective investigation of bispecific CD19/22 CAR T cell therapy in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Front Oncol. 2021;11:664421. https://doi.org/10.3389/fonc.2021.664421.

Article PubMed PubMed Central Google Scholar

Wei G, Zhang Y, Zhao H, et al. CD19/CD22 dual-targeted CAR T-cell therapy for relapsed/refractory aggressive B-cell lymphoma: a safety and efficacy study. Cancer Immunol Res. 2021;9(9):106170. https://doi.org/10.1158/2326-6066.CIR-20-0675.

Article CAS PubMed Google Scholar

Tong C, Zhang Y, Liu Y, et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood. 2020;136(14):163244. https://doi.org/10.1182/blood.2020005278.

Article PubMed PubMed Central Google Scholar

Shah NN, Johnson BD, Schneider D, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020;26(10):156975. https://doi.org/10.1038/s41591-020-1081-3.

Article CAS PubMed Google Scholar

Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. CAR-T cell therapy in T-cell malignancies: is success a low-hanging fruit? Stem Cell Res Ther. 2021;12(1):527. https://doi.org/10.1186/s13287-021-02595-0.

Article CAS PubMed PubMed Central Google Scholar

Read the original post:
Tumor buster - where will the CAR-T cell therapy missile go?

Posted in Cell Therapy | Comments Off on Tumor buster – where will the CAR-T cell therapy missile go?

National Medical Commission prohibits use of stem cell therapy to treat patients with autism – Hindustan Times

Posted: December 18, 2022 at 12:40 am

National Medical Commission prohibits use of stem cell therapy to treat patients with autism  Hindustan Times

See the original post:
National Medical Commission prohibits use of stem cell therapy to treat patients with autism - Hindustan Times

Posted in Cell Therapy | Comments Off on National Medical Commission prohibits use of stem cell therapy to treat patients with autism – Hindustan Times

Dr. Tau Braun and the Health Ranger talk transhumanism, AI infiltration …

Posted: December 18, 2022 at 12:37 am

For more updates, visit: http://www.brighteon.com/channel/hrreport

NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, were helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency.

Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/

Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html

Brighteon: https://www.brighteon.com/channels/hrreport

Join Our Social Network: https://brighteon.social/@HealthRanger

Check In Stock Products at: https://PrepWithMike.com

Brighteon.Social: https://brighteon.social/@HealthRanger

Parler: https://parler.com/#/user/naturalnews

Gettr: https://gettr.com/user/naturalnews

Gab: https://gab.ai/NaturalNews

Bitchute: https://www.bitchute.com/channel/naturalnews

Rumble: https://rumble.com/c/HealthRangerReport

Mewe: https://mewe.com/i/health.ranger

Spreely: https://www.spreely.com/page/NaturalNews

PureSocialNetwork: https://puresocialnetwork.com/profile/?NaturalNews/

Pinterest: https://www.pinterest.com/realhealthrangerstore/

See more here:
Dr. Tau Braun and the Health Ranger talk transhumanism, AI infiltration ...

Posted in Transhumanism | Comments Off on Dr. Tau Braun and the Health Ranger talk transhumanism, AI infiltration …

Nano Medicine: Meaning, Advantages and Disadvantages – BioTechnology Notes

Posted: December 18, 2022 at 12:36 am

In this article we will discuss about Nano Medicine:- 1. Meaning of Nano Medicine 2. Advantages of Nano Medicine 3. Disadvantages.

The application of nanotechnology in medicine is often referred to as Nano medicine. Nano medicine is the preservation and improvement of human health using molecular tools and molecular knowledge of the human body. It covers areas such as nanoparticle drug delivery and possible future applications of molecular nanotechnology (MNT) and Nano-vaccinology.

The human body is comprised of molecules. Hence, the availability of molecular nanotechnology will permit dramatic progress in human medical services. More than just an extension of molecular medicine, Nano medicine will help us understand how the biological machinery inside living cells operates at the Nano scale so that it can be employed in molecular machine systems to address complicated medical conditions such as cancer, AIDS, ageing and thereby bring about significant improvement and extension of natural human biological structure and function at the molecular scale.

Nano medical approaches to drug delivery centre on developing Nano scale particles or molecules to improve drug bioavailability that refers to the presence of drug molecules in the body part where they are actually needed and will probably do the most good. It is all about targeting the molecules and delivering drugs with cell precision.

The use of Nano robots in medicine would totally change the world of medicine once it is realized. For instance, by introducing these Nano robots into the body damages and infections can be detected and repaired. In short it holds that capability to change the traditional approach of treating diseases and naturally occurring conditions in the human beings.

1. Advanced therapies with reduced degree of invasiveness.

2. Reduced negative effects of drugs and surgical procedures.

3. Faster, smaller and highly sensitive diagnostic tools.

4. Cost effectiveness of medicines and disease management procedures as a whole.

5. Unsolved medical problems such as cancer, benefiting from the Nano medical approach.

6. Reduced mortality and morbidity rates and increased longevity in return.

1. Lack of proper knowledge about the effect of nanoparticles on biochemical pathways and processes of human body.

2. Scientists are primarily concerned about the toxicity, characterization and exposure pathways associated with Nano medicine that might pose a serious threat to the human beings and environment.

3. The societys ethical use of Nano medicine beyond the concerned safety issues, poses a serious question to the researchers.

Continued here:
Nano Medicine: Meaning, Advantages and Disadvantages - BioTechnology Notes

Posted in Nano medicine | Comments Off on Nano Medicine: Meaning, Advantages and Disadvantages – BioTechnology Notes

www.the-scientist.com

Posted: December 18, 2022 at 12:36 am

Both the academic community and the pharmaceutical industry are making increasing investments of time and money in nanotherapeutics. Nearly 50 biomedical products incorporating nanoparticles are already on the market, and many more are moving through the pipeline, with dozens in Phase 2 or Phase 3 clinical trials. Drugmakers are well on their way to realizing the prediction of Christopher Guiffre, chief business officer at the Cambridge, Massachusettsbased nanotherapeutics company Cerulean Pharma, who last November forecast, Five years from now every pharma will have a nano program.

Technologies that enable improved cancer detection are constantly racing against the diseases they aim to diagnose, and when survival depends on early intervention, losing this race can be fatal. While detecting cancer biomarkers is the key to early diagnosis, the number of bona fide biomarkers that reliably reveal the presence of cancerous cells is low. To overcome this challenge, researchers are developing functional nanomaterials for more sensitive detection of intracellular metabolites, tumor cellmembrane proteins, and even cancer cells that are circulating in the bloodstream. (See Fighting Cancer with Nanomedicine, The Scientist, April 2014.)

The extreme brightness, excellent photostability, and ready modulation of silica nanoparticles, along with other advantages, make them particularly useful for molecular imaging and ultrasensitive detection.

Silica nanoparticles are one promising material for detecting specific molecular targets. Dye-doped silica nanoparticles contain a large quantity of dye molecules housed inside a silica matrix, giving an intense fluorescence signal that is up to 10,000 times greater than that of a single organic fluorophore. Taking advantage of Frster Resonance Energy Transfer (FRET), in which a photon emitted by one fluorophore can excite another nearby fluorophore, researchers can synthesize fluorescent silica nanoparticles with emission wavelengths that span a wide spectrum by simply modulating the ratio of the different dyesthe donor chromophore and the acceptor chromophore. The extreme brightness, excellent photostability, and ready modulation of silica nanoparticles, along with other advantages, make them particularly useful for molecular imaging and ultrasensitive detection.

THE NANOMEDICINE CABINET: Scientists are engineering nanometer-size particles made of diverse materials to aid in patient care. The unique properties of these structures are making waves in biomedical analysis and targeted therapy.See full infographic: JPG | PDF TAMI TOLPAOther materials that are under investigation as nanodetectors include graphene oxide (GO), the monolayer of graphite oxide, which has unique electronic, thermal, and mechanical properties. Semiconductor-material quantum dots (QDs), now being developed by Shuming Nies group at Emory University, exhibit quantum mechanical properties when covalently coupled to biomolecules and could improve cancer imaging and molecular profiling.1 Spherical nucleic acids (SNAs), in which nucleic acids are oriented in a spherical geometry, scaffolded on a nanoparticle core (which may be retained or dissolved), are also gaining traction by the pioneering work of Chad Mirkins group at Northwestern University.2 (See illustration.)

Nanoparticles are also proving their worth as probes for various types of bioimaging, including fluorescence, magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET). For instance, Xiaoyuan Chen, now at the National Institutes of Healths National Institute of Biomedical Imaging and Bioengineering, and Hongjie Dai of Stanford University have developed carbon nanotubes for performing PET scans in mice. When modified with the macromolecule polyethylene glycol to improve biocompatibility, the nanotubes were very stable and remained in circulation for days, far longer than the few hours typical of many molecular imaging agents.3 Further modification with a short-peptide targeting ligand called RGD caused the nanotubes to selectively accumulate in tumors that overexpressed integrin, the molecular target of RGD, enabling precise tumor imaging.

To further increase the specificity of nanodetectors, researchers can add recognition probes such as aptamersshort synthetic nucleic acid strands that bind target molecules. For example, we conjugated gold nanoparticles with aptamers that had been identified through iteratively screening DNA probes using living cancer cells.4 Circulating tumor cells (CTCs) are shed into the bloodstream from primary tumors and provide a potential target for early cancer diagnosis. However, CTCs are rare, with blood concentrations of typically fewer than 10 cells per milliliter of blood. Collaborating with physicians to profile samples from leukemia patients, we demonstrated that aptamers are capable of differentiating among different subtypes of leukemia, as well as among patient samples before and after chemotherapy (unpublished data). In addition to leukemia, we have selected aptamers specific to cancers of the lung, liver, ovaries, colon, brain, breast, and pancreas, as well as to bacterial cells. Other researchers have developed nanoparticles with numerous and diverse surface aptamers, enabling them to bind their targets more efficiently and securely.

NANOCAPSULES: A false-color transmission electron micrograph of liposomes, spherical particles composed of a lipid bilayer around a central cavity that can be engineered to deliver both hydrophobic and hydrophilic drugs to specific cells in the body DAVID MCCARTHY/SCIENCE SOURCEThe prototype of targeted drug delivery can be traced back to the concept of a magic bullet, proposed by chemotherapy pioneer and 1908 Nobel laureate Paul Ehrlich. Ehrlich envisioned a drug that could selectively target a disease-causing organism or diseased cells, leaving healthy tissue unharmed. A century later, researchers are developing many types of nanoscale magic bullets that can specifically deliver drugs into target cells or tissues.

Doxil, the first nanotherapeutic approved by the US Food and Drug Administration, is a liposome (~100 nm in diameter) containing the widely used anticancer drug doxorubicin. The therapy takes advantage of the leaky blood vasculature and poor lymphatic drainage in tumor tissues that allow the nanoparticles to squeeze from blood vessels into a tumor and stay there for hours or days. Scientists have also been developing nanotherapeutics capable of targeting specific cell types by binding to surface biomarkers on diseased cells. Targeting ligands range from macromolecules, such as antibodies and aptamers, to small molecules, such as folate, that bind to receptors overexpressed in many types of cancers.

Aptamers in particular are a popular tool for targeting specific cells. Aptamer development is efficient and cost-effective, as automated nucleic acid synthesis allows easy, affordable chemical synthesis and modification of functional moieties. Other advantages include high stability and long shelf life, rapid tissue penetration based on the relatively small molecular weights, low immunogenicity, and ease of antidote development in the case of an adverse reaction to therapy by simply administering an aptamers complementary DNA. We have demonstrated the principle of modifying aptamers on the surfaces of doxorubicin-containing liposomes, which then selectively delivered the drug to cultured cancer cells.5

Recent advances in predicting the secondary structures of a DNA fragment or interactions between multiple DNA strands, as well as in technologies to automatically synthesize predesigned DNA sequences, has opened the door to more advanced applications of aptamers and other DNA structures in nanomedicine. For instance, we have developed aptamer-tethered DNA nanotrains, assembled from multiple copies of short DNA building blocks. On one end, an aptamer moiety allows specific target cell recognition during drug delivery, and a long double-stranded DNA section on the other end forms the boxcars for drug loading. The nanotrains, which can hold a high drug payload and specifically deliver anticancer drugs into target cancer cells in culture and animal models,6 could reduce drug side effects while inhibiting tumor growth. Alternatively, Daniel Anderson of MIT engineered a tetrahedral cage of DNA, often called DNA origami, for folate-mediated targeted delivery of small interfering RNAs (siRNAs) to silence some tumor genes.7 And Mirkins SNAs can similarly transport siRNAs as guided missiles to knock out overexpressed genes in cancer cells. Mirkins group also recently demonstrated that the SNAs were able to penetrate the blood-brain barrier and specifically target genes in the brains of glioblastoma animal models.2 Peng Yin of Harvard Medical School and the Wyss Institute and others are now building even more complex DNA nanostructures with refined functions, such as smart biomedical analysis.8

Conventional assembly of such DNA nanostructures exploits the hybridization of a DNA strand to part of its complementary strand. In addition, we have discovered that DNA nanostructures called nanoflowers because they resemble a ring of nanosize petals, can be self-assembled through liquid crystallization of DNA, which typically occurs at high concentrations of the nucleic acid.9 Importantly, these DNA nanostructures can be readily incorporated with components possessing multiple functionalities, such as aptamers for specific recognition, fluorophores for molecular imaging, and DNA therapeutics for disease therapy.

Another example of novel nanoparticles is DNA micelles, three-dimensional nanostructures that can be readily modified to include aptamers for specific cell-type recognition, or DNA antisense for gene silencing. The lipid core and sphere of projecting nucleic acids can enter cells without any transfection agents and have high resistance to nuclease digestion, making them ideal candidates for drug delivery and cancer therapy.

Researchers are developing many types of nanoscale magic bullets that can specifically deliver drugs into target cells or tissues.

Such advances in targeting are now making it possible to deliver combinations of drugs and ensure that they reach target cells simultaneously. Paula Hammond and Michael Yaffe of MIT recently reported a liposome-based combination chemotherapy delivery system that can simultaneously deliver two synergistic chemotherapeutic drugs, erlotinib and doxorubicin, for enhanced tumor killing.10 Erlotinib, an inhibitor of epidermal growth factor receptor (EGFR), promotes the dynamic rewiring of apoptotic pathways, which then sensitizes cancer cells to subsequent exposure to the DNA-damaging agent doxorubicin. By incorporating erlotinib, a hydrophobic molecule, into the lipid bilayer shell while packaging the hydrophilic doxorubicin inside of the liposomes, the researchers achieved the desired time sequence of drug releasefirst erlotinib, then doxorubicinin a one-two punch against the cancer. They also demonstrated that the efficiency of drug delivery to cancer cells was enhanced by coating the liposomes with folate.

Scientists are also engineering smart nanoparticles, which activate only in the disease microenvironment. For example, George Church of Harvard Medical School and the Wyss Institute and colleagues invented a logic-gated DNA nanocapsule that they programmed to deliver drugs inside cells only when a specific panel of disease biomarkers is overexpressed on the cell surface.11 And Donald Ingbers group, also at Harvard Medical School and the Wyss Institute, developed microscale aggregates of thrombolytic-drug-coated nanoparticles that break apart under the abnormally high fluid shear stress of narrowed blood vessels and then bind and dissolve the problematic clot.12

With these and other nanoplatforms for targeted drug delivery being tested in animal models, medicine is now approaching the prototypic magic bullet, sparing healthy tissue while exterminating disease.

In addition to serving as mere drug carriers that deliver the toxic payload to target cells, nanomaterials can themselves function as therapeutics. For example, thermal energy is emerging as an important means of therapy, and many gold nanomaterials can convert photons into thermal energy for targeted photothermal therapy. Taking advantage of these properties, we conjugated aptamers onto the surfaces of gold-silver nanorods, which efficiently absorb near-infrared light and convert energy from photons to heat. These aptamer-conjugated nanorods were capable of selectively binding to target cells in culture and inducing dramatic cytotoxicity by converting laser light to heat.13

Magnetic nanoparticles are also attractive for their ability to mediate heat induction. Jinwoo Cheon of Yonsei University in Korea developed coreshell magnetic nanoparticles, which efficiently generated thermal energy by a magnetization-reversal process as these nanoparticles returned to their relaxed states under an external, alternating-current magnetic field.14 Using this technology, Cheon and his colleagues saw dramatic tumor regression in a mouse model.A third type of nanosize therapeutic involves cytotoxic polymers. For example, we synthesized a nucleotide-like molecule called an acrydite with an attached DNA aptamer that specifically binds to and enters target cancer cells.15 The acrydite molecules in the resultant acrydite-aptamer conjugates polymerized with each other to form an aptamer-decorated molecular string that led to cytotoxicity in target cancer cells, including those exhibiting multidrug resistance, a common challenge in cancer chemotherapy.

Many other subfields have been advanced by recent developments in nanomedicine, including tissue engineering and regenerative medicine, medical devices, and vaccines. We must proceed with caution until these different technologies prove safe in patients, but nanomedicine is now poised to make a tremendous impact on health care and the practice of clinical medicine.

Guizhi Zhu is a postdoctoral associate in the Department of Chemistry and at the Health Cancer Center of the University of Florida. Weihong Tan is a professor and associate director of the Center for Research at the Bio/Nano Interface at the University of Florida. He also serves as the director of the Molecular Science and Biomedicine Laboratory at Hunan University in China, where Lei Mei is a graduate student.

Read the original post:
http://www.the-scientist.com

Posted in Nano medicine | Comments Off on www.the-scientist.com

Applications of Nanotechnology – National Nanotechnology Initiative

Posted: December 18, 2022 at 12:36 am

After more than 20 years of basic nanoscience research andmore than fifteen years of focused R&D under the NNI, applications of nanotechnology are delivering in both expected and unexpected ways on nanotechnologys promise to benefit society.

Nanotechnology is helping to considerably improve, even revolutionize, many technology and industry sectors: information technology, homeland security, medicine, transportation, energy, food safety, and environmental science, among many others. Described below is a sampling of the rapidly growing list of benefits and applications of nanotechnology.

Many benefits of nanotechnology depend on the fact that it is possible to tailor the structures of materials at extremely small scales to achieve specific properties, thus greatly extending the materials science toolkit. Using nanotechnology, materials can effectively be made stronger, lighter, more durable, more reactive, more sieve-like, or better electrical conductors, among many other traits. Many everyday commercial products are currently on the market and in daily use that rely on nanoscale materials and processes:

Nanotechnology has greatly contributed to major advances in computing and electronics, leading to faster, smaller, and more portable systems that can manage and store larger and larger amounts of information. These continuously evolving applications include:

Nanotechnology is already broadening the medical tools, knowledge, and therapies currently available to clinicians. Nanomedicine, the application of nanotechnology in medicine, draws on the natural scale of biological phenomena to produce precise solutions for disease prevention, diagnosis, and treatment. Below are some examples of recent advances in this area:

Nanotechnology is finding application in traditional energy sources and is greatly enhancing alternative energy approaches to help meet the worlds increasing energy demands. Many scientists are looking into ways to develop clean, affordable, and renewable energy sources, along with means to reduce energy consumption and lessen toxicity burdens on the environment:

In addition to the ways that nanotechnology can help improve energy efficiency (see the section above), there are also many ways that it can help detect and clean up environmental contaminants:

Nanotechnology offers the promise of developing multifunctional materials that will contribute to building and maintaining lighter, safer, smarter, and more efficient vehicles, aircraft, spacecraft, and ships. In addition, nanotechnology offers various means to improve the transportation infrastructure:

Please visit the Environmental, Health, and Safety Issues and the Ethical, Legal, and Societal Issues pages on nano.gov to learn more about how the National Nanotechnology Initiative is committed to responsibly addressing these issues.

Read the original here:
Applications of Nanotechnology - National Nanotechnology Initiative

Posted in Nano medicine | Comments Off on Applications of Nanotechnology – National Nanotechnology Initiative

Page 124«..1020..123124125126..130140..»